ARGX News and Press, argenx SE

July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...

2024-07-16 09:45:00 ET Summary With inflation slowing in many countries, equity markets saw modest returns in Q2. In a cooling equity market, the portfolio fell short of the MSCI EAFE Index and the MSCI All Country World ex USA Index in Q2. Our holdings in the materials sector...

2024-07-16 04:09:00 ET Summary TimesSquare Capital U.S. Small Cap Growth portfolio outperformed the Russell 2000® Growth Index in the second quarter. Our preferences in the Consumer-oriented sectors lean toward value-oriented or specialty retailers, franchise models, or premi...

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...

First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...

2024-07-12 09:00:07 ET Gavin Clark-Gartner from Evercore ISI issued a price target of $533.00 for ARGX on 2024-07-12 08:03:00. The adjusted price target was set to $533.00. At the time of the announcement, ARGX was trading at $461.72. The overall price target consensus i...

2024-07-10 12:19:05 ET Summary argenx SE's stock is down significantly from its all-time highs due to some clinical failures for its primary asset, Vyvgart. However, recent approval for a label expansion into CIDP has turned sentiment more positive, with the shares spurting forwar...

2024-07-10 08:25:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy lagged sl...

2024-07-09 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-28 10:20:00 ET Summary Argenx's shares rose after FDA approval of Vyvgart for the treatment of CIDP. The approval expands the addressable market for Vyvgart, and the company will initially target 12,000 patients in the U.S. who are currently not well controlled on other dr...